From: Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
Parameter | baseline | day 2 | day 14 | (male) | ||
---|---|---|---|---|---|---|
vehicle | Nz-800CW | vehicle | Nz-800CW | |||
mean ± sd | mean ± sd | mean ± sd | unit | |||
A:G Ratio | 1.5 ± 0.1 | 1.6 ± 0.1 | 1.6 ± 0.2 | 1.6 ± 0.0 | 1.7 ± 0.1 | |
ALT | 24.8 ± 5.0 | 27.6 ± 4.0 | 25.2 ± 4.1 | 27.2 ± 3.3 | 22.8 ± 2.6 | U/L |
Albumin | 28.5 ± 0.6 | 29.4 ± 1.1 | 29.4 ± 1.5 | 30.8 ± 1.8 | 31.5 ± 0.6 | g/L |
Alk Phos | 114 ± 9 | 131 ± 4 | 122 ± 11 | 123 ± 3 | 114 ± 7 | U/L |
Amylase | 2893 ± 836 | 3167 ± 247 | 2883 ± 127 | 3130 ± 223 | 3692 ± 764 | U/L |
CK | 310 ± 127 | 255 ± 187 | 217 ± 78 | 380 ± 131 | 356 ± 154 | U/L |
Calcium | 2.4 ± 0.3 | 2.5 ± 0.1 | 2.5 ± 0.1 | 2.6 ± 0.1 | 2.5 ± 0.1 | mmol/L |
Chloride | 105 ± 1 | 105 ± 2 | 105 ± 0.8 | 102 ± 1.5 | 104 ± 1.7 | mmol/L |
Cholesterol | 3.3 ± 0.2 | 3.3 ± 0.2 | 3.4 ± 0.1 | 3.2 ± 0.2 | 3.2 ± 0.2 | mmol/L |
Creatinine | 15.8 ± 3.0 | 15.5 ± 2.6 | 17.2 ± 2.4 | 17.8 ± 2.3 | 13.4 ± 2.3 | μmol/L |
GLDH | 7.2 ± 1.3 | 9.8 ± 1.9 | 8.6 ± 1.1 | 7.0 ± 0.7 | 6.0 ± 0.8 | U/L |
Globulin | 18.8 ± 1.0 | 19.0 ± 1.2 | 19.0 ± 1.4 | 19.2 ± 1.1 | 18.8 ± 1.0 | g/L |
Glucose | 15.4 ± 2.7 | 12.8 ± 1.7 | 13.8 ± 1.6 | 12.8 ± 2.8 | 13.8 ± 1.1 | mmol/L |
Lipase | 27.0 ± 0.8 | 27.4 ± 2.5 | 25.0 ± 4.2 | 28.4 ± 2.3 | 28.8 ± 1.8 | U/L |
Magnesium | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.2 ± 0.1 | 1.1 ± 0.1 | mmol/L |
Na:K Ratio | 35.5 ± 1.3 | 37.8 ± 2.8 | 41.5 ± 3.7 | 40.6 ± 7.1 | 38.5 ± 1.9 | |
Phosphorus | 2.9 ± 0.3 | 2.3 ± 0.5 | 2.5 ± 0.3 | 3.0 ± 0.2 | 2.6 ± 0.3 | mmol/L |
Potassium | 4.2 ± 0.2 | 4.1 ± 0.3 | 3.6 ± 0.3 | 3.7 ± 0.7 | 4.0 ± 0.2 | mmol/L |
Sodium | 151 ± 2 | 154 ± 3 | 150 ± 2 | 149 ± 2 | 151 ± 2 | mmol/L |
Total Bilirubin | 0.1 ± 0.2 | 0.3 ± 0.4 | 0.7 ± 0.4 | 0.2 ± 0.2 | 0.4 ± 0.5 | μmol/L |
Total Protein | 47.2 ± 1.0 | 48.4 ± 0.6 | 48.4 ± 0.6 | 50.0 ± 2.8 | 49.8 ± 1.6 | g/L |
Urea | 8.7 ± 0.2 | 10.4 ± 0.6 | 9.6 ± 1.1 | 9.8 ± 1.5 | 9.0 ± 1.5 | mmol/L |